314 related articles for article (PubMed ID: 21072752)
1. Molecular determination of RHD zygosity: predicting risk of hemolytic disease of the fetus and newborn related to anti-D.
Pirelli KJ; Pietz BC; Johnson ST; Pinder HL; Bellissimo DB
Prenat Diagn; 2010 Dec; 30(12-13):1207-12. PubMed ID: 21072752
[TBL] [Abstract][Full Text] [Related]
2. The use of maternal plasma for prenatal RhD blood group genotyping.
Finning K; Martin P; Daniels G
Methods Mol Biol; 2009; 496():143-57. PubMed ID: 18839110
[TBL] [Abstract][Full Text] [Related]
3. [Prenatal genotyping of the RhD locus by polymerase chain reaction in fetus at risk of hemolytic disease].
Misković B; Stipoljev F; Hadzisejdić I; Grahovac B
Lijec Vjesn; 2008; 130(1-2):4-6. PubMed ID: 18589635
[TBL] [Abstract][Full Text] [Related]
4. Molecular analysis of the RhD genotype in fetuses at risk for RhD hemolytic disease.
Spence WC; Maddalena A; Demers DB; Bick DP
Obstet Gynecol; 1995 Feb; 85(2):296-8. PubMed ID: 7824249
[TBL] [Abstract][Full Text] [Related]
5. Hemolytic disease of the fetus and newborn in the molecular era.
Fasano RM
Semin Fetal Neonatal Med; 2016 Feb; 21(1):28-34. PubMed ID: 26589360
[TBL] [Abstract][Full Text] [Related]
6. Prenatal RHD gene determination and dosage analysis by PCR: clinical evaluation.
Chan FY; Cowley NM; Wolter L; Stone M; Carmody F; Saul A; Hyland CA
Prenat Diagn; 2001 Apr; 21(4):321-6. PubMed ID: 11288127
[TBL] [Abstract][Full Text] [Related]
7. Determination of fetal RHD type in plasma of RhD negative pregnant women.
Sørensen K; Kjeldsen-Kragh J; Husby H; Akkök ÇA
Scand J Clin Lab Invest; 2018 Sep; 78(5):411-416. PubMed ID: 29869532
[TBL] [Abstract][Full Text] [Related]
8. Non-invasive fetal RHD and RHCE genotyping from maternal plasma in alloimmunized pregnancies.
Hromadnikova I; Vesela K; Benesova B; Nekovarova K; Duskova D; Vlk R; Spalova I; Gerychova R; Hakenova A; Rosenbaumova Z; Vlasin P; Vlachova A; Palasek V; Roznakova E; Calda P
Prenat Diagn; 2005 Dec; 25(12):1079-83. PubMed ID: 16231295
[TBL] [Abstract][Full Text] [Related]
9. Noninvasive fetal RhD genotyping from maternal blood.
Kolialexi A; Tounta G; Mavrou A
Expert Rev Mol Diagn; 2010 Apr; 10(3):285-96. PubMed ID: 20370586
[TBL] [Abstract][Full Text] [Related]
10. Severe hemolytic disease of fetus and newborn caused by red blood cell antibodies undetected at first-trimester screening (CME).
Dajak S; Stefanović V; Capkun V
Transfusion; 2011 Jul; 51(7):1380-8. PubMed ID: 21214583
[TBL] [Abstract][Full Text] [Related]
11. [Rh system genotyping in amniotic fluid].
Cotorruelo C; Biondi C; García Borrás S; Di Mónaco R; Martino W; Racca A
Medicina (B Aires); 2001; 61(1):76-8. PubMed ID: 11265629
[TBL] [Abstract][Full Text] [Related]
12. Use of a PCR-based assay for fetal Cw antigen genotyping in a patient with a history of moderately severe hemolytic disease of the newborn due to anti-Cw.
Reiner AP; Teramura G; Aramaki KM
Am J Perinatol; 1999; 16(6):277-81. PubMed ID: 10586980
[TBL] [Abstract][Full Text] [Related]
13. PCR-based determination of Rhc and RhE status of fetuses at risk of Rhc and RhE haemolytic disease.
Le Van Kim C; Mouro I; Brossard Y; Chavinié J; Cartron JP; Colin Y
Br J Haematol; 1994 Sep; 88(1):193-5. PubMed ID: 7803243
[TBL] [Abstract][Full Text] [Related]
14. [Applications of RHD zygosity test through polymerase chain reaction for prediction of fetus Rh D-positive phenotype].
Shao CP
Zhonghua Fu Chan Ke Za Zhi; 2003 Apr; 38(4):223-5. PubMed ID: 12885370
[TBL] [Abstract][Full Text] [Related]
15. Effect of screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands.
Koelewijn JM; Vrijkotte TG; van der Schoot CE; Bonsel GJ; de Haas M
Transfusion; 2008 May; 48(5):941-52. PubMed ID: 18248570
[TBL] [Abstract][Full Text] [Related]
16. The determination of the fetal D status from maternal plasma for decision making on Rh prophylaxis is feasible.
Müller SP; Bartels I; Stein W; Emons G; Gutensohn K; Köhler M; Legler TJ
Transfusion; 2008 Nov; 48(11):2292-301. PubMed ID: 18694461
[TBL] [Abstract][Full Text] [Related]
17. Fetal hemolytic disease due to anti-Rh17 alloimmunization.
Hirose M; Nakanishi K; Kaku S; Moro H; Hodohara K; Aotani H; Takebayashi K; Noda Y
Fetal Diagn Ther; 2004; 19(2):182-6. PubMed ID: 14764967
[TBL] [Abstract][Full Text] [Related]
18. RHD zygosity assignments based on most probable genotype and hybrid Rhesus box detection in Tunisia.
Kacem N; Chakroun T; Moussa H; Abdelkefi S; Houissa B; Chiaroni J; Jemni Yacoub S
Transfus Med; 2012 Oct; 22(5):362-6. PubMed ID: 22757646
[TBL] [Abstract][Full Text] [Related]
19. Fetal blood group genotyping from DNA from maternal plasma: an important advance in the management and prevention of haemolytic disease of the fetus and newborn.
Daniels G; Finning K; Martin P; Soothill P
Vox Sang; 2004 Nov; 87(4):225-32. PubMed ID: 15585017
[TBL] [Abstract][Full Text] [Related]
20. [Prenatal determination of fetal rhesus factor in amnionic cells using polymerase chain reaction].
Crombach G; Picard F; Beckmann MW; Niederacher D; Bender HG
Geburtshilfe Frauenheilkd; 1995 Oct; 55(10):577-9. PubMed ID: 8543131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
